secwatch.observer — SEC 8-K summary
======================================

Issuer:     Codiak BioSciences, Inc. (—)
CIK:        0001659352
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001193125-23-079964
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.03, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codiak BioSciences files Chapter 11, seeks asset sale, cuts 69% of staff, top executives exit
--------------------------------------------------------------------------------

- Filed voluntary Chapter 11 petition in Delaware on March 27, 2023; intends to sell substantially all assets through a court-supervised process.
- Reduced workforce by 34 employees (69%); estimates ~$1.12M in severance and termination costs.
- CEO Douglas Williams, CFO Linda Bain, CMO David Mauro, CSO Sriram Sathyanarayanan, Chief Legal Officer Yalonda Howze, and VP HR Nicole Barna departing in early April 2023; Williams remains on board.
- Appointed Paul Huygens of Province, LLC as Chief Restructuring Officer to manage the sale process and operations during Chapter 11.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659352/000119312523079964/0001193125-23-079964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659352/000119312523079964/d467120d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-079964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer